The Chronic Bronchitis drugs in development market research report provides comprehensive information on the therapeutics under development for Chronic Bronchitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Chronic Bronchitis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Chronic Bronchitis and features dormant and discontinued products.
GlobalData tracks ten drugs in development for Chronic Bronchitis by ten companies/universities/institutes. The top development phase for Chronic Bronchitis is phase i with three drugs in that stage. The Chronic Bronchitis pipeline has ten drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Chronic Bronchitis pipeline products market are: PharmaLundensis, Chiesi Farmaceutici and AstraZeneca.
The key targets in the Chronic Bronchitis pipeline products market include Phosphodiesterase 4, Mercury, and Muscarinic Acetylcholine Receptor M3.
The key mechanisms of action in the Chronic Bronchitis pipeline product include Phosphodiesterase 4 Inhibitor with one drug in Phase III. The Chronic Bronchitis pipeline products include four routes of administration with the top ROA being Inhalational and three key molecule types in the Chronic Bronchitis pipeline products market including Small Molecule, and Monoclonal Antibody.
Chronic Bronchitis overview
Chronic Bronchitis is a type of chronic obstructive pulmonary disease (COPD) that refers to long-term inflammation of the bronchi. This is a productive cough of more than 3 months occurring within a span of 2 years.
For a complete picture of Chronic Bronchitis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
